We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
FLY LDN is a fitness brand that imparts sports and fitness instruction via its digital platform and its studios in central London and Fitzrovia. The company launched its video-on-demand and live-streaming fitness platform, FLY LDN Online (FLO), in September 2020. It asserts that within six months of launch, FLO scaled over 28,000 monthly views across 80+ countries with users having viewed over 2.5 million minutes of FLY LDN workouts. FLY LDN won the Men's Health 'Best Studio 2019' award and was commended at the 2018 and 2019 Tatler Gym Awards. The company has also received press coverage in publications like Women's Health, Forbes, Esquire, Elle, Vogue, GQ and Glamour. It has also partnered with brands such as DKNY and ASOS. FLY LDN aspires to become a contender in the global online fitness market that is expected to reach $59 billion by 2027. The company will use the investment to further develop additional functionality and TV apps for FLO and fund marketing campaigns to fuel growth.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £340,928
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go: Expired investment: £5,877,517
Please watch the video for more information
days to go: Expired investment: £964,550
Forth allows users to track their wellbeing to see what impact their lifestyle is having on their health. It allows users to maximise their performance during athletics, keep track of their inner health and focus on things they may need to work on for greater overall wellbeing. 
days to go: Expired investment: £165,760
GP Nutrition is a nutrition company that creates products meant to deliver sustainable weight loss. This award-winning company was created by Gabriela Peacock, a celebrity nutritionist. It has 13,000 global customers who have bought more than 30,000 packs. In June'19, the company reached trading of £50k per month. It has produced 22 products that are now sold in 30 countries. GP Nutrition has delivered revenue of £377k and an EBITDA of £813,389. Nutrition's vision is to solve the 95% failure rate of diets in the USA and the UK.
days to go: Expired investment: £309,890
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph